| Ciprofloxacin + fluocinolone acetonide |
Glucocorticoid; bacterial Top II |
Otitis media; otitis externa |
02-Jan-2025 |
| Erdafitinib |
FGFR1; FGFR2; FGFR3; FGFR4 |
Urothelial cell carcinoma (UCC) |
08-Jan-2025 |
| Prusogliptin |
DPP-4 |
Type 2 diabetes |
08-Jan-2025 |
| Limertinib |
BTK; EGFR T790M; ITK |
Non-small cell lung cancer (NSCLC) |
14-Jan-2025 |
| Senaparib |
PARP1; PARP2 |
Ovarian cancer (OVC); fallopian tube cancer; peritoneal cancer |
14-Jan-2025 |
| Ceftolozane + tazobactam |
PBP; β -lactamase |
Intra-abdominal infection (IAI); hospital-acquired bacterial pneumonia (HABP); ventilator-associated bacterial pneumonia (VABP); urinary tract infection (UTI) |
08-Feb-2025 |
| Netanasvir |
NS5A |
Chronic hepatitis C |
08-Feb-2025 |
| Encofosbuvir |
NS5B polymerase |
Chronic hepatitis C |
08-Feb-2025 |
| Telavancin |
/ |
Hospital-acquired bacterial pneumonia (HABP); ventilator-associated bacterial pneumonia (VABP) |
11-Feb-2025 |
| Tenapanor |
NHE3 |
Hyperphosphatemia in chronic kidney disease |
20-Feb-2025 |
| Inavolisib |
PI3K α |
Hormone receptor-positive breast cancer |
11-Mar-2025 |
| Tazemetostat |
EZH2 |
Follicular lymphoma (FL) |
18-Mar-2025 |
| Ivarmacitinib |
JAK1 |
Rheumatoid arthritis (RA); ankylosing spondylitis (AS); atopic dermatitis; alopecia areata |
18-Mar-2025 |
| Tafluprost + timolol |
β -adrenergic receptor; PGF2 α |
Glaucoma or ocular hypertension |
25-Mar-2025 |
| Suraxavir marboxil |
CEN |
Influenza |
25-Mar-2025 |
| Ibrexafungerp |
Glucan synthase |
Vulvovaginal candidiasis (VVC) |
01-Apr-2025 |
| Pemafibrate |
PPAR α |
Hypertriglyceridemia (HTG) |
08-Apr-2025 |
| Capivasertib |
Akt-1; Akt-2; Akt-3 |
Hormone receptor-positive breast cancer |
15-Apr-2025 |
| Adapalene + benzoyl peroxide |
RAR γ ; RAR β |
Acne vulgaris |
30-Apr-2025 |
| Asciminib |
STAMP |
Chronic myeloid leukemia (CML) |
13-May-2025 |
| Anrikefon |
κ opioid receptor |
Uremic pruritus; post-operative pain |
13-May-2025 |
| Bireociclib |
CDK2; CDK4; CDK6 |
Hormone receptor-positive breast cancer |
13-May-2025 |
| Lemborexant |
OX1R; OX2R |
Insomnia |
20-May-2025 |
| Allisartan + sacubitril |
AT1R; NEP |
Hypertension |
20-May-2025 |
| Glecirasib |
KRAS G12C |
Non-small cell lung cancer (NSCLC) |
20-May-2025 |
| Onradivir |
PB2 |
Influenza |
20-May-2025 |
| Retagliptin + metformin |
DPP-4; PEN2 |
Type 2 diabetes |
20-May-2025 |
| HR20013 |
5-HT3 receptor; NK1 |
Chemotherapy-induced nausea and vomiting (CINV) |
27-May-2025 |
| Allisartan isoproxil + indapamide |
AT1R; NCC |
Hypertension |
27-May-2025 |
| Deutenzalutamide |
AR |
Prostate cancer |
27-May-2025 |
| Famitinib |
PDGFR; c-Kit; VEGFR |
Cervical cancer |
27-May-2025 |
| Fovinaciclib |
CDK4; CDK6 |
Hormone receptor-positive breast cancer |
27-May-2025 |
| Gecacitinib |
JAK1; JAK2; JAK3; TYK2; ALK2 |
Myelofibrosis (MF) |
27-May-2025 |
| Lerociclib |
CDK4; CDK6 |
Hormone receptor-positive breast cancer |
27-May-2025 |
| Luvometinib |
MEK1; MEK2 |
Neurofibromatosis; Langerhans cell histiocytosis (LCH) |
27-May-2025 |
| Revefenacin |
M3 receptor |
Chronic obstructive pulmonary disease (COPD) |
10-Jun-2025 |
| Daridorexant |
OX1R; OX2R |
Insomnia |
17-Jun-2025 |
| Aztreonam + avibactam |
PBP; β -lactamase |
Intra-abdominal infection (IAI); hospital-acquired bacterial pneumonia (HABP); ventilator-associated bacterial pneumonia (VABP) |
24-Jun-2025 |
| Mazdutide |
GLP-1R; GCGR; OXM |
Type 2 diabetes; obesity or overweight |
24-Jun-2025 |
| Perfluorohexyloctane |
/ |
Dry eye syndrome (DES); meibomian gland dysfunction (MGD) |
30-Jun-2025 |
| Encorafenib |
BRAF |
Colorectal cancer (CRC) |
30-Jun-2025 |
| Ifupinostat |
HDAC; PI3K |
Diffuse large B-cell lymphoma (DLBCL) |
30-Jun-2025 |
| Tibremciclib |
CDK4; CDK6 |
Hormone receptor-positive breast cancer |
30-Jun-2025 |
| TPN171 |
PDE5 |
Erectile dysfunction (ED) |
08-Jul-2025 |
| Lisaftoclax |
Bcl-2 |
Chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL) |
08-Jul-2025 |
| ZX-7101A |
CEN |
Influenza |
15-Jul-2025 |
| Tunodafil |
PDE5 |
Erectile dysfunction (ED) |
22-Jul-2025 |
| Lazertinib |
EGFR T790M |
Non-small cell lung cancer (NSCLC) |
29-Jul-2025 |
| Atrasentan |
ETA |
IgA nephropathy (IgAN) |
19-Aug-2025 |
| XZP-3621 |
ALK; ROS1 |
Non-small cell lung cancer (NSCLC) |
19-Aug-2025 |
| Zongertinib |
HER2 |
Non-small cell lung cancer (NSCLC) |
26-Aug-2025 |
| Zeprumetostat |
EZH2 |
Peripheral T-cell lymphoma (PTCL) |
26-Aug-2025 |
| Fexuprazan |
Proton pump |
Gastro-esophageal reflux disease (GERD); reflux esophagitis |
02-Sep-2025 |
| Tolvaptan sodium phosphate |
AVPR2 |
Heart failure; body fluid retention; congestive heart failure; cardiac edema |
30-Sep-2025 |
| Zilucoplan |
C5 |
Myasthenia gravis (MG) |
30-Sep-2025 |
| Mufemilast |
PDE4 |
Plaque psoriasis |
30-Sep-2025 |
| Relmapirazin |
/ |
Renal function assessment |
14-Oct-2025 |
| Nerandomilast |
PDE4B |
Idiopathic pulmonary fibrosis (IPF); progressive pulmonary fibrosis (PPF) |
21-Oct-2025 |
| Mefatinib |
EGFR; HER2 |
Non-small cell lung cancer (NSCLC) |
21-Oct-2025 |
| Retagliptin + henagliflozin + metformin |
DPP-4; SGLT2; PEN2 |
Type 2 diabetes |
21-Oct-2025 |
| Olgotrelvir |
SARS-CoV-2 3CLpro; CTSL |
COVID-19 |
28-Oct-2025 |
| Sarecycline |
30S subunit |
Acne vulgaris |
04-Nov-2025 |
| Mometasone furoate + olopatadine |
Glucocorticoid; H1 receptor |
Allergic rhinitis |
04-Nov-2025 |
| Lutetium Lu 177 vipivotide tetraxetan |
PSMA |
Prostate cancer |
04-Nov-2025 |
| Visepegenatide |
GLP-1R |
Type 2 diabetes |
12-Nov-2025 |
| 68 Ga-gozetotide |
PSMA |
Prostate cancer |
25-Nov-2025 |
| Remibrutinib |
BTK |
Chronic spontaneous urticaria (CSU) |
25-Nov-2025 |
| Solriamfetol |
DAT; NET |
Obstructive sleep apnea (OSA); excessive daytime sleepiness (EDS) |
03-Dec-2025 |
| Cenobamate |
GABAA receptor; sodium channel |
Epilepsy; seizure; generalized tonic-clonic seizure (GTCS); focal onset seizure; status epilepticus (SE); photosensitive epilepsy |
03-Dec-2025 |
| SPH3127 |
Renin |
Hypertension |
03-Dec-2025 |
| Fitusiran |
AT III |
Hemophilia |
09-Dec-2025 |
| Culmerciclib |
CDK2; CDK4; CDK6 |
Hormone receptor-positive breast cancer |
09-Dec-2025 |
| Pixavir marboxil |
CEN |
Influenza |
09-Dec-2025 |
| Zurletrectinib |
Trk |
NTRK fusion-positive solid tumors |
09-Dec-2025 |
| Aficamten |
Myosin |
Hypertrophic cardiomyopathy (HCM) |
16-Dec-2025 |
| Pimicotinib |
CSF-1R |
Tenosynovial giant cell tumor (TGCT) |
16-Dec-2025 |
| Eplontersen |
TTR |
Transthyretin familial amyloid polyneuropathy (TTR-FAP) |
22-Dec-2025 |
| Xanomeline + trospium chloride |
mAChR; M1 receptor; M4 receptor |
Schizophrenia |
22-Dec-2025 |
| Serdexmethylphenidate + dexmethylphenidate |
DAT; NET |
Attention deficit hyperactivity disorder (ADHD) |
30-Dec-2025 |
| Sonrotoclax |
Bcl-2 |
Chronic lymphocytic leukemia (CLL); mantle cell lymphoma (MCL); small lymphocytic lymphoma (SLL) |
30-Dec-2025 |
